Intropin

(Dopamine)

ApprovedSmall molecule

Dopamine is used to treat low blood pressure and improve heart function in critically ill patients, typically given in hospital settings through an IV.[2] Intropin is currently approved and in use across 22 indications[4].[1]

Intropin is one of 476 small molecule programs targeting Neurodegenerative Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

475

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Neurodegenerative DiseaseActive, not recruiting

Premature BirthApproved

Cardiovascular DiseaseActive, not recruiting

Renal Artery StenosisActive, not recruiting

Depressive DisorderApproved

Cognitive ImpairmentApproved

Insulin SecretionActive, not recruiting

Parkinson DiseaseActive, not recruiting

AtherosclerosisActive, not recruiting

ShockApproved

Neurodegenerative DiseasePreclinical

Active, not recruiting

Premature BirthApproved

Approved

Cardiovascular DiseaseApproved

Active, not recruiting

Renal Artery StenosisPreclinical

Active, not recruiting

Depressive DisorderApproved

Approved

Cognitive ImpairmentApproved

Approved

Insulin SecretionPhase 1

Active, not recruiting

Parkinson DiseaseApproved

Active, not recruiting

AtherosclerosisPreclinical

Active, not recruiting

ShockApproved

Approved

Showing 10 of 22 indications

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Intropin

Pfizer

Approved

3 2

Zemplar

AbbVie

Preclinical

—3

Zoloft

VViatris Specialty LLC

Preclinical

2 4

Coumadin

AAbbott

Preclinical

1 5

Sulfonylureas

Eli Lilly

Preclinical

1 6

Thiazolidinediones

Sanofi

Preclinical

1 7

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 8

Meglitinides

Sanofi

Preclinical

1 9

Kuvan

BioMarin Pharmaceutical

Preclinical

1 10

Adriamycin

GGynecologic Oncology Group

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Recruiting

Hypotension

NCT05347238

Q2 2027

N/ARecruiting

Renal Artery Stenosis

NCT06447740

Q1 2029

PreclinicalNot yet recruiting

Pulmonary Arterial Hypertension (PAH)

NCT07667829

Q3 2029

N/ANot yet recruiting

Atherosclerosis

NCT07111442

Clinical

Trials by Indication[1]

Heart Failure3 trials

Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study

Completed·—·Phase 2·NCT01132846·360 enrolled

Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction

Completed·JJohns Hopkins University·Phase 4·NCT01901809·90 enrolled

AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT06611423·10 enrolled

Septic Shock2 trials

Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock

Completed·RRush University Medical Center·Phase 3·NCT00604019·252 enrolled

Adrenaline V/s Dopamine in Fuid Refractory Septic Shock

Recruiting·LLaiba Qamar·N/A·NCT07273526·90 enrolled

Atherosclerosis2 trials

A Placebo-controlled Trial of Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Among Atherosclerosis Renal-vascular Hypertension Patients

Not yet recruiting·PPeking University First Hospital·N/A·NCT07111442·200 enrolled

Fractional Flow Reserve to Determine Atherosclerosis Renovascular Hypertension Stenting

Recruiting·PPeking University First Hospital·N/A·NCT05732077·100 enrolled

Hypotension2 trials

Dopamine Versus Dobutamine for Treatment of Arterial Hypotension in Term and Preterm Neonates

Unknown status·UUniversity of Ulm·Phase 4·NCT01427686·20 enrolled

Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis

Recruiting·MMount Sinai Hospital, Canada··NCT05347238·550 enrolled

Exercise1 trial

The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise

Completed·UUniversity of Alberta·N/A·NCT02965963·49 enrolled

17 more indications

Blood Pressure Management1 trial

Early Blood Pressure Management in Extremely Premature Infants

Completed·NNICHD Neonatal Research Network·Phase 1·NCT00874393·10 enrolled

Oxygenation1 trial

Vasopressors for Cerebral Oxygenation

Unknown status·SSamsung Medical Center·Phase 1·NCT02009007·50 enrolled

Low Birth Weight1 trial

Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants

Completed·—·N/A·NCT01318278·70 enrolled

Renal Transplant Recipients1 trial

The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function

Unknown status·—·Phase 2/3·NCT03107858·44 enrolled

Renal artery stenosis1 trial

Fractional Flow Reserve-guided Stenting Versus Medical Therapy in Atherosclerosis Renal Artery Stenosis

Recruiting·PPeking University First Hospital·N/A·NCT06447740·200 enrolled

Sepsis1 trial

Microcirculation Guided Therapy Versus "Standard Treatment" of Severe Sepsis

Unknown status·OOnze Lieve Vrouwe Gasthuis·Phase 4·NCT00484133·80 enrolled

Laparoscopic Surgery1 trial

Renal Function During Laparoscopic Surgery

Completed·—·N/A·NCT01722630·60 enrolled

Blood Pressure1 trial

Decision Support for Intraoperative Low Blood Pressure

Completed·VVanderbilt University Medical Center·N/A·NCT02726620·22,435 enrolled

TIA1 trial

Potentiation of Procedural Motor Learning in Health and Disease

Terminated·UUniversity Hospital Muenster·Phase 4·NCT00126087·18 enrolled

General Anesthesia1 trial

Dopamine Versus Norepinephrine Under General Anesthesia

Completed·—·Phase 3·NCT04536194·60 enrolled

Acute Kidney Injury1 trial

The Comparative Effectiveness of Alprostadil,Sodium Ferulate and Dopamine in Pediatric Acute Kidney Injury

Unknown status·SShengjing Hospital·Phase 4·NCT03892447·300 enrolled

ESS1 trial

The Effect of Norepinephrine and Dopamine on Radial Forearm Free Flap Tissue Oxygen Pressure and Microdialysate Metabolite Measurements

Completed·TTampere University Hospital·Phase 4·NCT02241083·25 enrolled

Dexmedetomidine1 trial

Effects of Dexmedetomidine and Dopamine on Renal Function After Major Surgery

Unknown status·TTao Zhang·Phase 4·NCT03170739·180 enrolled

Brain Injury1 trial

Target Hemodynamics and Brain Injury During General Anesthesia in the Elderly

Suspended·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 2/3·NCT02428062·1,812 enrolled

Insulin Secretion1 trial

Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects

Completed·—·Phase 1·NCT02053935·15 enrolled

Pulmonary Arterial Hypertension (PAH)1 trial

Comparison of the Efficacy and Safety of Dopamine, Norepinephrine and Epinephrine in the Treatment of Pulmonary Hypertensive Crisis Under Hemodynamic Monitoring

Not yet recruiting·CChina National Center for Cardiovascular Diseases·Preclinical·NCT07667829·75 enrolled

Unspecified1 trial

Dopamine in Neonate

Unknown status·SSeoul National University Hospital·Phase 2·NCT04525495·30 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

INTROPIN

NDA NDA017395

Jan 1, 1982

DOPAMINE HYDROCHLORIDE

NDA NDA018132

Jan 1, 1982

DOPAMINE HYDROCHLORIDE

NDA NDA018014

Jan 1, 1982

DOPAMINE HYDROCHLORIDE

NDA NDA018138

Jan 1, 1982

DOPAMINE HYDROCHLORIDE

NDA NDA018398

Mar 11, 1983

DOPAMINE HYDROCHLORIDE

NDA NDA018549

Jun 28, 1983

DOPAMINE HYDROCHLORIDE

NDA NDA018656

Sep 30, 1983

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

NDA NDA018826

Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

NDA NDA019099

Mar 27, 1987

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

NDA NDA019615

Aug 30, 1995

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%

NDA NDA020542

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Dopamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Intropin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Dopamine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Dopamine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020542). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Beta-1 Adrenergic Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Pfizer

Intropin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q1 2029

Q3 2029

Trials by Indication[1]

Heart Failure3 trials

Septic Shock2 trials

Atherosclerosis2 trials

Hypotension2 trials

Exercise1 trial

Blood Pressure Management1 trial

Oxygenation1 trial

Low Birth Weight1 trial

Renal Transplant Recipients1 trial

Renal artery stenosis1 trial

Sepsis1 trial

Laparoscopic Surgery1 trial

Blood Pressure1 trial

TIA1 trial

General Anesthesia1 trial

Acute Kidney Injury1 trial

ESS1 trial

Dexmedetomidine1 trial

Brain Injury1 trial

Insulin Secretion1 trial

Pulmonary Arterial Hypertension (PAH)1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News